DPDjura Piersma

Djura Piersma

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Djura Piersma has a total of 121 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Associations between spatial distribution of immune cell subsets and clinical outcomes in patients with advanced melanoma treated with immune checkpoint inhibitors: results from the PUMA challenge

    by Mark Schuiveling, Hong Liu, Daniel Eek, Martina Hanusová, Isabella A.J. van Duin, Laurens Sebastian ter Maat, Janneke C. van der Weerd, Franchette W.P.J. van Den Berkmortel, Christian U. Blank, Gerben E. Breimer, et al.

    Patients with advanced melanoma are treated with immune checkpoint inhibitors (ICIs), yet less than 50% of patients achieve a durable response while all patients are exposed to the risk of severe side effects. Tumor-infiltrating lymphocytes (TILs) in pathology images are associated with ICI outcomes, but manual assessment is subjective. In addition, the predictive value of other immune cell subsets, including plasma cells, neutrophils, histiocytes, and melanophages, remains unclear. We organized the Panoptic segmentation of nUclei and tissue in advanced MelanomA (PUMA) challenge to evaluate whether the spatial localization of TILs and other immune cell subsets on melanoma H&E slides collected before start of treatment was associated with treatment outcomes. Algorithm performance was evaluated on a hidden test set, after which top-ranked algorithms were applied to pre-treatment metastatic whole-slide images from a large, multicenter cohort of patients with advanced melanoma treated with first-line ICIs ( n =1102). Automatically quantified tissue features and immune cell subsets were then associated with clinical outcomes. Top-performing algorithms improved detection of immune cell subsets, although accuracy for rare classes remained limited. Across challenge participants, TIL density showed the most consistent association with treatment response and survival. Associations for stromal TILs were weaker, while plasma cells, histiocytes, melanophages, neutrophils, necrosis and blood vessels did not show independent associations with outcomes. Overall, the results from the PUMA challenge improved the state of the art of immune cell detection in melanoma histopathology and show that intra-tumoral lymphocytes are the immune cell subset most consistently associated with treatment response and survival. Highlights: We organized the first melanoma-specific tissue and nuclei segmentation competition Winning algorithms were applied to 1102 whole-slide images for biomarker analysis Intra-tumoral TILs were associated with response to immune checkpoint inhibitors Other immune cell subsets showed no independent association with treatment outcomes Tissue segmentation on WSIs was limited by low heterogeneity in training data. Graphical

  • Open Access

    AI-detected tumor-infiltrating lymphocytes for predicting outcomes in anti-PD1 based treated melanoma

    by Mark Schuiveling, Isabella A.J. van Duin, Laurens ter Maat, Janneke C. van der Weerd, Rik J. Verheijden, Franchette van Den Berkmortel, Christian U. Blank, Gerben E. Breimer, Femke H. Burgers, Marye Boers-Sonderen, et al.

    Importance: Easy and accessible biomarkers to predict response to immune checkpoint inhibition (ICI)-treated melanoma are limited. Objective: To evaluate artificial intelligence (AI) detected tumor-infiltrating lymphocytes (TILs) on pretreatment melanoma metastases as a biomarker for response and survival in ICI-treated patients. Design: Multicenter cohort study including patients with advanced melanoma treated with first-line anti-PD1 ± anti-CTLA4 between 2016 and 2023. Median follow-up was 36.3 months. Setting: 11 melanoma treatment centers in the Netherlands. Participants: 1,202 patients with advanced cutaneous melanoma. Exposure: All patients received first-line anti-PD1 ± anti-CTLA4. Main Outcome(s) and Measure(s): The percentage of TILs inside manually annotated tumor area in H&E stained pretreatment metastases was determined using the Hover-NeXt model trained and evaluated on an independent melanoma dataset containing 166,718 pathologist-verified manually annotated cells. The primary outcome was objective response rate (ORR); secondary outcomes were progression-free survival (PFS) and overall survival (OS). Correlation with manual TILs, scored according to the guidelines stated by the immune-oncology working group, was evaluated with Spearman correlation coefficients. Logistic regression and Cox proportional regression were conducted, adjusted for age, sex, disease stage, ICI type, BRAF status, brain metastases, LDH level, and performance status. Results: Metastatic melanoma specimens were available for 1,202 patients, of whom 423 received combination therapy. Median TIL percentage was 9.9% (range 0.3% - 69.4%). A 10% increase in TILs was associated with increased ORR (adjusted OR 1.40 [95% 1.23-1.59]), PFS (adjusted HR 0.85 [95% CI 0.79 – 0.92]) and OS (adjusted HR 0.83 [95% CI 0.76 – 0.91]. Results were consistent for both patients treated with anti-PD1 monotherapy and combination treatment with anti-PD1 plus anti-CTLA4. When comparing manual TIL scoring with AI-detected TILs, associations with response and survival were consistently stronger for AI-detected TILs. Conclusions and Relevance: In patients with advanced melanoma, higher levels of AI-detected TILs on pre-treatment H&E slides were independently associated with improved ICI response and survival. Given the accessibility of TIL scoring on routine histology, TILs may serve as a predictive biomarker for ICI outcomes. To facilitate broader validation, the Hover-NeXt architecture and model weights are publicly available. Key points: Question: What is the predictive value of artificial intelligence-detected tumor-infiltrating lymphocytes (TILs) for clinical outcomes in patients with advanced melanoma receiving first-line immune checkpoint inhibition? Findings: In this multicenter cohort of 1202 patients, TILs in pretreatment metastases were quantified using a melanoma-specific publicly available AI model trained on an independent dataset. A 10% increase was associated with response (aOR 1.40 [95% CI 1.23–1.59]), progression-free survival (aHR 0.85 [95% CI 0.79–0.92]), and overall survival (aHR 0.83 [95% CI 0.76–0.91]). Associations were independent of clinical predictors. Meaning: AI-detected TILs in pretreatment melanoma metastases independently correlate with response and survival.


  • Open Access

    Adverse Events in Anti-PD-1-Treated Adjuvant and First-Line Advanced Melanoma Patients

    by Daan Jan Willem Rauwerdink, Olivier van Not, Melissa de Meza, Remco van Doorn, Jos van der Hage, A. J. M. van Den Eertwegh, John B. Haanen, Maureen J. B. Aarts, Franchette W. P. J. van Den Berkmortel, Christiaan U. Blank, et al.

    Introduction: The difference in incidence and severity of anti-PD-1 therapy-related adverse events (irAEs) between adjuvant and advanced treated melanoma patients remains unclear, as no head-to-head studies have compared these groups. Methods: This multi-center cohort study analyzed melanoma patients treated with anti-PD-1 in adjuvant or advanced settings between 2015 and 2021. Comorbidities and ECOG performance status were assessed before treatment, and grade III-IV irAEs were monitored during treatment. Univariate and multivariate regression analyses were conducted to identify factors associated with irAE development. Results: A total of 1465 advanced melanoma patients and 908 resected melanoma patients received anti-PD-1 therapy. Adjuvant-treated patients were younger, with a median age of 63 years compared to 69 years in the advanced group (p < 0.01), and had a better ECOG performance status (p < 0.01). Comorbidities were seen more frequently in advanced melanoma patients than in those receiving adjuvant treatment, 76% versus 68% (p < 0.01). Grade III-IV irAEs occurred in 214 (15%) advanced treated patients and in 119 (13%) adjuvant-treated patients. Multivariate analysis showed an increased risk of severe irAE development with the presence of any comorbidity (adjusted OR 1.22, 95% CI 1.02–1.44) and ECOG status greater than 1 (adjusted OR 2.00, 95% CI 1.20–3.32). Adjuvant therapy was not associated with an increased risk of irAE development compared to advanced treatment (adjusted OR 0.95, 95% CI 0.74–1.21) after correcting for comorbidities and ECOG performance score. Anti-PD-1 therapy was halted due to toxicity (any grade irAE) more often in the adjuvant setting than in the advanced setting, 20% versus 15% (p < 0.01). Conclusions: Higher ECOG performance status and presence of any comorbidity were independently associated with an increased risk of Grade III-IV irAE in adjuvant and advanced treated melanoma patients. Patients treated in the adjuvant setting did not have an increased risk of developing severe irAEs compared to advanced melanoma patients. These findings are of clinical significance in consulting patients for adjuvant anti-PD-1 treatment.


  • Open Access

    Baseline tumor-infiltrating lymphocyte patterns and response to immune checkpoint inhibition in metastatic cutaneous melanoma

    by Isabella A.J. van Duin, Mark Schuiveling, Laurens S. ter Maat, Wouter A.C. van Amsterdam, Franchette van Den Berkmortel, Marye Boers-Sonderen, Jan Willem B. de Groot, Geke A.P. Hospers, Ellen Kapiteijn, Mariette Labots, et al.


  • Open Access

    A Survival Tree of Advanced Melanoma Patients with Brain Metastases Treated with Immune Checkpoint Inhibitors

    by Olivier J. van Not, Thijs T. Wind, Rawa K. Ismail, Arkajyoti Bhattacharya, Mathilde Jalving, Christian U. Blank, Maureen J. B. Aarts, Franchette W. P. J. van Den Berkmortel, Marye J. Boers-Sonderen, Alfonsus J. M. van Den Eertwegh, et al.

    The efficacy of immune checkpoint inhibitors (ICIs) in patients with advanced melanoma that develop brain metastases (BM) remains unpredictable. In this study, we aimed to identify prognostic factors in patients with melanoma BM who are treated with ICIs. Data from advanced melanoma patients with BM treated with ICIs in any line between 2013 and 2020 were obtained from the Dutch Melanoma Treatment Registry. Patients were included from the time of the treatment of BM with ICIs. Survival tree analysis was performed with clinicopathological parameters as potential classifiers and overall survival (OS) as the response variable. In total, 1278 patients were included. Most patients were treated with ipilimumab–nivolumab combination therapy (45%). The survival tree analysis resulted in 31 subgroups. The median OS ranged from 2.7 months to 35.7 months. The strongest clinical parameter associated with survival in advanced melanoma patients with BM was the serum lactate dehydrogenase (LDH) level. Patients with elevated LDH levels and symptomatic BM had the worst prognosis. The clinicopathological classifiers identified in this study can contribute to optimizing clinical studies and can aid doctors in giving an indication of the patients’ survival based on their baseline and disease characteristics.


  • Open Access

    Adjuvant treatment of in‐transit melanoma: Narrowing the knowledge gap left by clinical trials

    by Melissa M. de Meza, Willeke A. M. Blokx, Han J. Bonenkamp, Cristian U. Blank, Maureen J. B. Aarts, Franchette W. P. J. van Den Berkmortel, Marye J. Boers‐Sonderen, Jan Willem B. de Groot, John B. Haanen, Geke A. P. Hospers, et al.

    Few clinical trials address efficacy of adjuvant systemic treatment in patients with in-transit melanoma (ITM). This study describes adjuvant systemic therapy of ITM patients beyond clinical trials. In this study, we included stage III adjuvant-treated melanoma patients registered in the nationwide Dutch Melanoma Treatment Registry between July 2018 and December 2020. Patients were divided into three groups: nodal disease only, ITM only and ITM and nodal disease. Recurrence patterns, recurrence-free survival (RFS) and overall survival (OS) at 12-months were analyzed. In our study population of 1037 patients, 66.8% had nodal disease only, 16.7% had ITM only and 16.2% had ITM with nodal disease. RFS at 12-months was comparable in the nodal only and ITM only group (72.2% vs70.1%, P = .97) but lower in ITM and nodal disease patients (57.8%; P = .01, P < .01). Locoregional metastases occurred as first recurrence in 38.9% nodal disease only, 71.9% of ITM-only and 44.0% of ITM and nodal disease patients. Distant recurrences occurred in 42.3%, 18.8% and 36.0%, respectively (P = .02). 12-months OS was not significantly different for nodal disease only patients compared with ITM-only (94.4% vs 97.6%, P = .06) but was significantly higher for ITM-only compared with ITM and nodal disease patients (97.6% vs 91.0%, P < .01). In conclusion, we showed that in the adjuvant setting, RFS rates in ITM-only patients are similar to non-ITM, though better than in ITM and nodal disease patients. Adjuvant-treated ITM-only patients less often experience distant recurrences and have a superior OS compared with ITM and nodal disease patients.


  • Open Access

    Adjuvant BRAF-MEK Inhibitors versus Anti PD-1 Therapy in Stage III Melanoma: A Propensity-Matched Outcome Analysis

    by Melissa M. De Meza, Willeke A. M. Blokx, Johannes J. Bonenkamp, Christian U. Blank, Maureen J. B. Aarts, Franchette W. P. J. van Den Berkmortel, Marye J. Boers-Sonderen, Jan Willem B. De Groot, John B. A. G. Haanen, Geke A. P. Hospers, et al.

    Adjuvant BRAF/MEK- and anti-PD-1 inhibition have significantly improved recurrence-free survival (RFS) compared to placebo in resected stage III BRAF-mutant melanoma. However, data beyond the clinical trial setting are limited. This study describes the toxicity and survival of patients treated with adjuvant BRAF/MEK inhibitors and compares outcomes to adjuvant anti-PD-1. For this study, stage III BRAF V600 mutant cutaneous melanoma patients treated with adjuvant BRAF/MEK-inhibition or anti-PD-1 were identified from the Dutch Melanoma Treatment Registry. BRAF/MEK- and anti-PD-1-treated patients were matched based on propensity scores, and RFS at 12 and 18 months were estimated. Between 1 July 2018 and 31 December 2021, 717 patients were identified. Of these, 114 patients with complete records were treated with BRAF/MEK therapy and 532 with anti-PD-1. Comorbidities (p = 0.04) and geographical region (p < 0.01) were associated with treatment choice. In 45.6% of BRAF/MEK-treated patients, treatment was prematurely discontinued. Grade ≥ 3 toxicity occurred in 11.5% of patients and was the most common cause of early discontinuation (71.1%). At 12 and 18 months, RFS in BRAF/MEK-treated patients was 85% and 70%, compared to 68% and 68% in matched anti-PD-1-treated patients (p = 0.03). In conclusion, comorbidities and geographical region determine the choice of adjuvant treatment in patients with resected stage III BRAF-mutant melanoma. With the currently limited follow-up, BRAF/MEK-treated patients have better RFS at 12 months than matched anti-PD-1-treated patients, but this difference is no longer observed at 18 months. Therefore, longer follow-up data are necessary to estimate long-term effectiveness.


  • Open Access

    Systemic Therapy in Advanced Nodular Melanoma versus Superficial Spreading Melanoma: A Nation-Wide Study of the Dutch Melanoma Treatment Registry

    by Daan Jan Willem Rauwerdink, Remco van Doorn, Jos van der Hage, Alfonsus J. M. Van Den Eertwegh, John B. A. G. Haanen, Maureen Aarts, Franchette Berkmortel, Christian U. Blank, Marye J. Boers-Sonderen, Jan Willem B. De Groot, et al.

    Nodular melanoma (NM) is associated with a higher locoregional and distant recurrence rate compared with superficial spreading melanoma (SSM); it is unknown whether the efficacy of systemic therapy is limited. Here, we compare the efficacy of immunotherapy and BRAF/MEK inhibitors (BRAF/MEKi) in advanced NM to SSM. Patients with advanced stage IIIc and stage IV NM and SSM treated with anti-CTLA-4 and/or anti-PD-1, or BRAF/MEKi in the first line, were included from the prospective Dutch Melanoma Treatment Registry. The primary objectives were distant metastasis-free survival (DMFS) and overall survival (OS). In total, 1086 NM and 2246 SSM patients were included. DMFS was significantly shorter for advanced NM patients at 1.9 years (CI 95% 0.7–4.2) compared with SSM patients at 3.1 years (CI 95% 1.3–6.2) (p < 0.01). Multivariate survival analysis for immunotherapy and BRAF/MEKi demonstrated a hazard ratio for immunotherapy of 1.0 (CI 95% 0.85–1.17) and BRAF/MEKi of 0.95 (CI 95% 0.81–1.11). A shorter DMFS for NM patients developing advanced disease compared with SSM patients was observed, while no difference was observed in the efficacy of systemic immunotherapy or BRAF/MEKi between NM and SSM patients. Our results suggests that the worse overall survival of NM is mainly driven by propensity of metastatic outgrowth of NM after primary diagnosis.


  • Open Access

    BRAF and NRAS Mutation Status and Response to Checkpoint Inhibition in Advanced Melanoma

    by Olivier J. van Not, Willeke A.M. Blokx, Alfons J.M. van Den Eertwegh, Melissa M. de Meza, John B. Haanen, Christian U. Blank, Maureen J.B. Aarts, Franchette W.P.J. van Den Berkmortel, Jan Willem B. de Groot, Geke A.P. Hospers, et al.

    PURPOSE: Little is known about the effect of specific gene mutations on efficacy of immune checkpoint inhibitors in patients with advanced melanoma. MATERIALS AND METHODS: All patients with advanced melanoma treated with first-line anti–PD-1 or ipilimumab-nivolumab between 2012 and 2021 in the nationwide Dutch Melanoma Treatment Registry were included in this cohort study. Objective response rate, progression-free survival (PFS), and overall survival (OS) were analyzed according to BRAF and NRAS status. A multivariable Cox model was used to analyze prognostic factors associated with PFS and OS. RESULTS: In total, 1764 patients received anti–PD-1 and 759 received ipilimumab-nivolumab. No significant differences in PFS were found in the anti–PD-1 cohort. In the ipilimumab-nivolumab cohort, median PFS was significantly higher for BRAF-mutant melanoma (9.9 months; 95% CI, 6.8 to 17.2) compared with NRAS-mutant (4.8 months; 95% CI, 3.0 to 7.5) and double wild-type (5.3 months; 95% CI, 3.6 to 7.1). In multivariable analysis, BRAF-mutant melanoma was significantly associated with a lower risk of progression or death in the ipilimumab-nivolumab cohort. Median OS was significantly higher for BRAF-mutant melanoma compared with NRAS-mutant and double wild-type melanoma for both immune checkpoint inhibitor regimens. CONCLUSION: Ipilimumab-nivolumab–treated patients with BRAF-mutant melanoma display improved PFS and OS compared with patients with NRAS-mutant and double wild-type melanoma. BRAF mutation status is a factor to consider while choosing between mono and dual checkpoint inhibition in advanced melanoma.


  • Open Access

    Hospital Variation in Cancer Treatments and Survival OutComes of Advanced Melanoma Patients: Nationwide Quality Assurance in The Netherlands

    by Jesper van Breeschoten, Alfonsus J. M. van Den Eertwegh, Liesbeth C. de Wreede, Doranne L. Hilarius, Erik W. van Zwet, John B. Haanen, Christian U. Blank, Maureen J. B. Aarts, Franchette W. P. J. van Den Berkmortel, Jan Willem B. de Groot, et al.

    Background: To assure a high quality of care for patients treated in Dutch melanoma centers, hospital variation in treatment patterns and outcomes is evaluated in the Dutch Melanoma Treatment Registry. The aim of this study was to assess center variation in treatments and 2-year survival probabilities of patients diagnosed between 2013 and 2017 in the Netherlands. Methods: We selected patients diagnosed between 2013 and 2017 with unresectable IIIC or stage IV melanoma, registered in the Dutch Melanoma Treatment Registry. Centers’ performance on 2-year survival was evaluated using Empirical Bayes estimates calculated in a random effects model. Treatment patterns of the centers with the lowest and highest estimates for 2-year survival were compared. Results: For patients diagnosed between 2014 and 2015, significant center variation in 2-year survival probabilities was observed even after correcting for case-mix and treatment with new systemic therapies. The different use of new systemic therapies partially explained the observed variation. From 2016 onwards, no significant difference in 2-year survival was observed between centers. Conclusion: Our data suggest that between 2014 and 2015, after correcting for patient case-mix, significant variation in 2-year survival probabilities between Dutch melanoma centers existed. The use of new systemic therapies could partially explain this variation. In 2013 and between 2016 and 2017, no significant variation between centers existed.